Of clinical importance, increased expression and activity of CHKα and choline transporters have also spurred the successful development of radiolabeled choline analogs, [11C]-choline or [18F]-fluorocholine, as tracers for positron emission tomography/computed tomography (PET/CT) in diagnostic imaging of cancer patients for detection, staging and monitoring response to therapies [2,5]. Here, CHKA is linked to cancer.